Aquinox Pharmaceuticals

Canaccord Genuity is pleased to announce that on September 15, 2015, it completed an underwritten public offering of common shares for Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ: AQXP). Aquinox issued a total of 6,325,000 shares of common stock, including 825,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $15.50 per share. Canaccord Genuity acted as joint book-running manager for the offering.

Aquinox intends to use the net proceeds from this offering to conduct Phase 3 trials for AQX-1125 in bladder pain syndrome/interstitial cystitis (BPS/IC), to fund research and development costs to advance its pipeline, including its preclinical product candidates, and for working capital and other general corporate purposes.

Aquinox is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.